| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | |||||||||
Net loss | |||||||||
-76,282 | -56,671 | -27,319 | -21,873 | -14,526 | -26,778 | 4,449 | -10,532 | -2,532 | -7,537 |
Adjustments to reconcile net loss to cash used in operating activities: | |||||||||
(Gain) on change in fair value of derivative-warrants | |||||||||
- | - | - | - | - | - | 271 | 1,236 | 3,580 | - |
Loss on change in fair value of derivative-preferred stock | |||||||||
- | - | - | - | - | -23,110 | 8,010 | -4,770 | 1,410 | - |
Gain on change in fair value of derivative - warrants | |||||||||
- | - | - | - | - | - | - | - | - | 4,621 |
Loss on change in fair value of derivative - preferred stock | |||||||||
- | - | - | - | - | - | - | - | - | 5,840 |
Warrant extension expense | |||||||||
- | - | - | - | - | - | - | 2,316 | 0 | - |
Gain on negotiated payables | |||||||||
- | - | - | - | - | - | - | 241 | 1,324 | 509 |
Depreciation and amortization | |||||||||
7,819 | 2,360 | 741 | 825 | 551 | 11 | 3 | 419 | 233 | 238 |
Stock option-based compensation expense | |||||||||
7,338 | 8,178 | 4,644 | 4,829 | 4,368 | - | - | - | - | - |
Restricted stock-based compensation expense | |||||||||
899 | 688 | 1,272 | 3,432 | - | - | - | - | - | - |
Accretion and interest on short-term investments | |||||||||
266 | 626 | - | - | - | - | - | - | - | - |
Accretion of right-of-use lease assets | |||||||||
858 | - | - | - | - | - | - | - | - | - |
Net gain on write-off of licensed technology | |||||||||
- | - | -127 | - | - | - | - | - | - | - |
Non-cash earnings on investments | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Non-cash loss on arbitration ruling on licensing agreement | |||||||||
367 | - | - | - | - | - | - | - | - | - |
Net gain on write-off of licensed technology | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Change in operating assets and liabilities: | |||||||||
Receivables | |||||||||
-81 | -26 | -17 | 9 | 79 | -39 | -766 | 507 | -685 | 982 |
Inventory | |||||||||
- | - | - | - | - | - | -194 | 43 | 151 | - |
Prepaid expenses and other current assets | |||||||||
-670 | 1,067 | 2,580 | -160 | 287 | -77 | -174 | 212 | -31 | 28 |
Other assets | |||||||||
- | - | - | 4 | - | - | - | - | - | - |
Restricted cash | |||||||||
- | - | - | - | - | - | - | -330 | 330 | -17 |
Other assets | |||||||||
-3 | -40 | 11 | - | 29 | 0 | -10 | -17 | 15 | - |
Accounts payable, accrued expenses and lease liabilities | |||||||||
1,707 | -7,665 | 1,301 | - | - | - | - | - | - | - |
Payable to licensor | |||||||||
2,600 | - | - | - | - | - | - | - | - | - |
Accounts payable and accrued expenses | |||||||||
- | - | - | 2,819 | -1,174 | - | - | - | - | - |
Stock option compensation expense | |||||||||
- | - | - | - | - | 1,305 | 439 | 390 | 1,066 | 1,015 |
Stock issued to directors, employees and consultants | |||||||||
- | - | - | - | -4,852 | 0 | - | - | - | - |
Stock issued to directors and employees | |||||||||
- | - | - | - | - | - | -167 | - | - | - |
Stock issued to directors and employees | |||||||||
- | - | - | - | - | - | - | -305 | 0 | - |
Stock issued for services | |||||||||
- | - | - | - | 401 | 349 | 111 | 77 | 602 | 925 |
Contingent consideration milestone | |||||||||
- | - | - | -2,591 | - | - | - | - | - | - |
Accounts payable and accrued expenses | |||||||||
- | - | - | - | - | 33 | -1,176 | 567 | 53 | -601 |
Interest on dividends payable | |||||||||
- | - | - | - | - | 592 | 279 | - | - | - |
Contingent consideration milestone | |||||||||
- | - | - | - | -3,898 | 0 | - | - | - | - |
Dividends payable | |||||||||
- | - | - | - | - | - | - | 319 | 271 | 168 |
Accrued interest payable | |||||||||
- | - | - | - | - | - | - | -98 | -28 | -437 |
Deferred revenue | |||||||||
- | 296 | 2,009 | -602 | -602 | -349 | 2,866 | -596 | -1,180 | -348 |
Net cash used in operating activities | |||||||||
- | - | - | - | -10,423 | -1,611 | 1 | - | - | - |
Net cash used in operating activities | |||||||||
-62,820 | -39,111 | -22,655 | -13,014 | - | - | - | -3,955 | -7,609 | -6,860 |
Cash flows from investing activities: | |||||||||
Capital expenditures | |||||||||
6,309 | 9,243 | 860 | 519 | 308 | 0 | 2 | 13 | 40 | 7 |
Acquisition of licensed technology | |||||||||
199 | 10,251 | - | 0 | - | - | - | - | - | - |
Purchases of short-term investments | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Proceeds from maturities of short-term investments | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Purchases of short-term investments | |||||||||
- | 136,092 | - | - | - | - | - | - | - | - |
Proceeds from maturities of short-term investments | |||||||||
66,484 | 70,500 | - | - | - | - | - | - | - | - |
Payment of short-term debt | |||||||||
- | - | - | - | 400 | - | - | - | - | - |
Proceeds from $4.00 common stock net of costs | |||||||||
- | - | - | - | - | 12,307 | - | - | - | - |
Net cash (used in) provided by investing activities | |||||||||
59,976 | -85,086 | -860 | -519 | - | - | - | -13 | -40 | -7 |
Cash flows from financing activities: | |||||||||
Proceeds from issuance of common stock and pre-funded warrants in public offering, net of offering costs | |||||||||
95,972 | - | - | - | - | - | - | - | - | - |
Proceeds from issuance of common stock in public offering, net of offering costs | |||||||||
- | - | 86,174 | - | - | - | - | - | - | - |
Cash from Abeona Ohio acquisition | |||||||||
- | - | - | - | 3,697 | 0 | - | - | - | - |
Net cash used in investing activities | |||||||||
- | - | - | - | 3,389 | 0 | -2 | - | - | - |
Proceeds from open market sales of common stock | |||||||||
16,961 | - | - | - | - | 0 | 0 | - | - | 13,101 |
Proceeds from $8.00 common stock issuances net of costs | |||||||||
- | - | - | - | - | 0 | - | - | - | - |
Proceeds from $5.50 common stock issuances net of costs | |||||||||
- | - | - | - | - | 0 | - | - | - | - |
Proceeds from exercise of $5.00 warrants | |||||||||
- | 3,233 | 885 | - | 4,635 | 0 | - | - | - | - |
Payment of debt | |||||||||
- | - | - | - | - | - | - | 2,750 | 2,750 | - |
Proceeds from exercise of stock options | |||||||||
969 | 2,244 | 344 | 350 | 0 | - | 29 | 0 | - | 192 |
Proceeds from exercise of $8.00 warrants | |||||||||
- | - | 5,000 | - | - | - | - | - | - | - |
Proceeds from $2.85 restricted common stock issuance | |||||||||
- | - | - | 150 | 0 | - | - | - | - | - |
Proceeds/payment of short-term debt | |||||||||
- | - | - | - | - | 400 | 0 | - | - | - |
Net cash provided by financing activities | |||||||||
- | - | - | - | 35,652 | 12,707 | 29 | - | - | - |
Proceeds from preferred stock issuances, net of costs | |||||||||
- | - | - | - | - | - | - | 4,654 | 5,826 | - |
Net cash provided by financing activities | |||||||||
113,902 | 5,477 | 92,403 | 42,537 | - | - | - | 1,904 | 3,076 | 13,293 |
Net (decrease) increase in cash, cash equivalents and restricted cash | |||||||||
111,058 | -118,720 | 68,888 | 29,004 | - | - | - | - | - | - |
Supplemental cash flow information: | |||||||||
Net increase in cash and cash equivalents | |||||||||
- | - | - | - | 28,618 | 11,096 | 28 | -2,064 | -4,573 | 6,426 |
Payable for acquisition of licensed technology | |||||||||
- | 30,000 | - | - | - | - | - | - | - | - |
Write off of licensed asset and corresponding liability | |||||||||
- | - | 4,000 | - | - | - | - | - | - | - |
Shares returned in connection with arbitration ruling on licensing agreement | |||||||||
1,472 | - | - | - | - | - | - | - | - | - |
Payable for acquistion of licensed technology | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Cash paid for interest | |||||||||
- | - | - | - | 7 | 7 | 0 | 388 | 720 | -874 |
Write off of licensed asset and corresponding liability | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Shares issued to EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation for licenses | |||||||||
- | - | - | 2,452 | - | - | - | - | - | - |
Cash paid for interest | |||||||||
- | 11 | 8 | 6 | - | - | - | - | - | - |
Shares issued to holders of Abeona Ohio for acquisition | |||||||||
- | - | - | - | 31,758 | 0 | - | - | - | - |
Contingent milestones to Abeona Ohio members | |||||||||
- | - | - | - | 6,489 | 0 | - | - | - | - |
Licensed technology from Abeona Ohio | |||||||||
- | - | - | - | 2,156 | 0 | - | - | - | - |
Shares issued to EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation for licenses | |||||||||
- | - | - | 2,452 | 0 | - | - | - | - | - |
Conversion of Series A preferred stock unpaid dividends and interest into shares of common stock | |||||||||
- | - | - | - | - | - | 0 | - | - | - |
Conversion of Series B preferred stock unpaid dividends and interest and liquidated damages into shares of common stock | |||||||||
- | - | - | - | - | - | 0 | - | - | - |
Cancel treasury stock | |||||||||
- | - | - | - | - | 4 | 0 | - | - | - |
Payable in cash or future issuance of common shares for licensed technology | |||||||||
- | - | - | - | - | 5,000 | 0 | - | - | - |
Shares issued for dividends on preferred stock | |||||||||
- | - | - | - | - | - | - | 22 | 1 | - |
Warrants issued for placement agent fees | |||||||||
- | - | - | - | - | - | - | - | 39 | -274 |
Preferred stock dividends in dividends payable | |||||||||
- | - | - | - | - | 2,875 | 2,898 | 1,999 | 1,774 | - |
Dividends payable exchanged for preferred stock | |||||||||
- | - | - | - | - | - | - | 5,297 | 0 | - |
Shares issued for dividends on preferred stock (in shares) | |||||||||
- | - | - | - | - | - | - | - | - | 288 |
Preferred stock dividends in dividends payable | |||||||||
- | - | - | - | - | - | - | - | - | -1,791 |
Private Placement One [Member] | |||||||||
Proceeds From Issuance Of Common Stock | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Private Placement Two [Member] | |||||||||
Proceeds From Issuance Of Common Stock | |||||||||
- | - | - | 41,068 | - | - | - | - | - | - |
Private Placement Three [Member] | |||||||||
Proceeds From Issuance Of Common Stock | |||||||||
- | - | - | 969 | - | - | - | - | - | - |
Dollar Five Warrant | |||||||||
Proceeds from exercise of $5.00 warrants | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Dollar Eight Warrant [Member] | |||||||||
Proceeds from Warrant Exercises | |||||||||
- | - | - | 0 | - | - | - | - | - | - |